Reconstitution is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-06. Numbers and descriptions here follow the published literature rather than marketing material.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
A nerve is an enclosed, cable-like bundle of nerve fibers (called axons). Nerves have historically been considered the basic units of the peripheral nervous system. A nerve provides a common pathway for the electrochemical nerve impulses called action potentials that are transmitted along each of the axons to peripheral organs or, in the case of sensory nerves, from the periphery back to the central nervous system. Each axon is an extension of an individual neuron, along with other supportive cells such as some Schwann cells that coat the axons in myelin. Each axon is surrounded by a layer of connective tissue called the endoneurium. The axons are bundled together into groups called fascicles, and each fascicle is wrapped in a layer of connective tissue called the perineurium. The entire nerve is wrapped in a layer of connective tissue called the epineurium. Nerve cells (often called neurons) are further classified as either sensory or motor. In the central nervous system, the analogous structures are known as nerve tracts.
== Application in forensic science == The ability of the Coomassie dye to target amino acids with aromatic groups (phenylalanine, tyrosine, tryptophan) and basic side chains (lysine, arginine and histidine) allows the Bradford assay to be used for fingerprint analysis. The assay was successfully used to identify the biological sex of the fingerprint. Female samples were shown to have a higher absorbance than male samples when tested at similar wavelengths. This provides a simpler method for fingerprint analysis by reducing the number of amino acids needing to be analyzed from 23 to 6 and requires little to no assay preparation, in contrast to the ninhydrin chemical assay, which requires assay preparation such as heating and enzyme cascade.
==== Adenoma of the adrenal gland ==== Adrenal adenomas are benign tumors of the adrenal gland. In most cases, the tumors display no symptoms and require no treatment. In rare cases, however, some adrenal adenomas may become activated. When activated, the adenoma begins to produce hormones in much larger quantities than what the adrenal glands would normally produce, leading to health complications including primary aldosteronism and hyperandrogenism.
=== EC 1.5.1 With NAD+ or NADP+ as acceptor === EC 1.5.1.1: 1-piperideine-2-carboxylate/1-pyrroline-2-carboxylate reductase (NAD(P)H) EC 1.5.1.2: pyrroline-5-carboxylate reductase EC 1.5.1.3: dihydrofolate reductase EC 1.5.1.4: Now included with EC 1.5.1.3 dihydrofolate reductase EC 1.5.1.5: methylenetetrahydrofolate dehydrogenase (NADP+) EC 1.5.1.6: formyltetrahydrofolate dehydrogenase EC 1.5.1.7: saccharopine dehydrogenase (NAD+, L-lysine-forming) EC 1.5.1.8: saccharopine dehydrogenase (NADP+, L-lysine-forming) EC 1.5.1.9: saccharopine dehydrogenase (NAD+, L-glutamate-forming) EC 1.5.1.10: saccharopine dehydrogenase (NADP+, L-glutamate-forming) EC 1.5.1.11: D-octopine dehydrogenase EC 1.5.1.12: Now EC 1.2.1.88, L-glutamate γ-semialdehyde dehydrogenase EC 1.5.1.13: Now EC 1.17.1.5, nicotinate dehydrogenase EC 1.5.1.14: Now included with EC 1.5.1.21 Δ1-piperideine-2-carboxylate reductase EC 1.5.1.15: methylenetetrahydrofolate dehydrogenase (NAD+) EC 1.5.1.16: D-lysopine dehydrogenase EC 1.5.1.17: alanopine dehydrogenase EC 1.5.1.18: ephedrine dehydrogenase EC 1.5.1.19: D-nopaline dehydrogenase EC 1.5.1.20: methylenetetrahydrofolate reductase (NAD(P)H) EC 1.5.1.21: 1-piperideine-2-carboxylate/1-pyrroline-2-carboxylate reductase (NADPH) EC 1.5.1.22: strombine dehydrogenase EC 1.5.1.23: tauropine dehydrogenase EC 1.5.1.24: N5-(carboxyethyl)ornithine synthase EC 1.5.1.25: thiomorpholine-carboxylate dehydrogenase EC 1.5.1.26: β-alanopine dehydrogenase EC 1.5.1.27: 1,2-dehydroreticulinium reductase (NADPH) EC 1.5.1.28: opine dehydrogenase EC 1.5.1.29: Now covered by EC 1.5.1.38 [FMN reductase (NADPH)], EC 1.5.1.39 [FMN reductase [NAD(P)H])] and EC 1.5.1.41 (riboflavin reductase [NAD(P)H]) EC 1.5.1.30: flavin reductase (NADPH) EC 1.5.1.31: berberine reductase EC 1.5.1.32: vomilenine reductase EC 1.5.1.33: pteridine reductase EC 1.5.1.34: 6,7-dihydropteridine reductase EC 1.5.1.35: identical to EC 1.2.1.19, aminobutyraldehyde dehydrogenase, as the substrates 1-pyrroline and 4-aminobutanal are interconvertible EC 1.5.1.36: flavin reductase (NADH) EC 1.5.1.37: FAD reductase (NADH) EC 1.5.1.38: FMN reductase (NADPH) EC 1.5.1.39: FMN reductase (NAD(P)H) EC 1.5.1.40: 8-hydroxy-5-deazaflavin:NADPH oxidoreductase EC 1.5.1.41: riboflavin reductase (NAD(P)H) EC 1.5.1.42: FMN reductase (NADH) EC 1.5.1.43: carboxynorspermidine synthase EC 1.5.1.44: festuclavine dehydrogenase EC 1.5.1.45: FAD reductase (NAD(P)H) EC 1.5.1.46: agroclavine dehydrogenase EC 1.5.1.47: dihydromethanopterin reductase [NAD(P)+] EC 1.5.1.48: 2-methyl-1-pyrroline reductase EC 1.5.1.49: 1-pyrroline-2-carboxylate reductase [NAD(P)H] EC 1.5.1.50: dihydromonapterin reductase EC 1.5.1.51: N-[(2S)-2-amino-2-carboxyethyl]-L-lutamate dehydrogenase EC 1.5.1.52: staphylopine dehydrogenase EC 1.5.1.53: methylenetetrahydrofolate reductase (NADPH) EC 1.5.1.54: methylenetetrahydrofolate reductase (NADH)
=== Location and Position === The apical foramen is the principal opening at a tooth's root terminus, serving as the conduit between the root canal system and the periapical tissues. Its location is variable, as it frequently deviates from the anatomical apex—the root's geometric tip. Studies indicate that in a majority of cases, the foramen is positioned laterally, most commonly on the distal aspect. The average deviation is typically less than 1 millimeter, though greater distances are observed in specific teeth such as mandibular canines and molars. The foramen's morphology is often oval but can be circular or irregular. Its precise location and shape can be influenced by ethnic background, age, and physiological changes. In clinical endodontics, accurate identification of the apical foramen, rather than reliance on the radiographic apex alone, is essential for determining the correct working length and ensuring treatment success.
Sources: en.wikipedia.org
A complicating factor is that a single ion channel may have multiple internal "gates" that respond to changes in Vm in opposite ways, or at different rates. For example, although raising Vm opens most gates in the voltage-sensitive sodium channel, it also closes the channel's "inactivation gate", albeit more slowly. Hence, when Vm is raised suddenly, the sodium channels open initially, but then close due to the slower inactivation. The voltages and currents of the action potential in all of its phases were modeled accurately by Alan Lloyd Hodgkin and Andrew Huxley in 1952, for which they were awarded the Nobel Prize in Physiology or Medicine in 1963. However, their model considers only two types of voltage-sensitive ion channels, and makes several assumptions about them, e.g., that their internal gates open and close independently of one another. In reality, there are many types of ion channels, and they do not always open and close independently.
Recombinant human parathyroid hormone is an artificially manufactured form of the parathyroid hormone used to help treat hypoparathyroidism (under-active parathyroid glands) and osteoporosis. Recombinant human parathyroid hormone (Preotact) received market authorization in the European Union in April 2006 to treat osteoporosis in postmenopausal women at high risk of fractures. Preotact marketing authorisation was later voluntarily withdrawn in 2014 by the holder NPS Pharma. FDA approval (as Preos) was not granted in the US for the same indication due to hypercalcemia and injection device issues. Recombinant human parathyroid hormone (Natpara) was approved for medical use in the United States in January 2015, and received (as Natpar) conditional market authorization in the European Union in February 2017 as orphan drug. On 2019 Natpara was recalled in the US due to rubber particle issues emerging from daily use of the cartridge. Takeda announced in 2022 its decision to stop manufacturing Natpara/Natpar globally at the end of 2024.
SIMS and FAB are quite similar. SIMS uses an ion beam, usually Ar+ or Cs+. FAB uses a neutral atom beam, usually Ar or Xe. For SIMS and FAB, if the matrix compound is more acidic than the analyte, then predominantly (M + H)+ forms formed, and conversely (M − H)−. Also possibly forming (M + Na)+, (M + K)+, etc, if the matrix is contaminated incidentally (adventitiously) by sodium, potassium, etc. Typical matrix materials include glycerol, thioglycerol, 3-nitrobenzyl alcohol, diethanolamine, triethanolamine, and dithiothreitol-dithioerythritol mixture. They are usually used to analyze polypeptides and oligonucleotides up to 20 kDa. MALDE uses a photon beam, usually the soft-UV 337 nm nitrogen laser. It can also use an infrared (IR) laser for direct analysis of samples contained in gels or thin-layer chromatography (TLC) plates. MALDE can analyze small polymers (~1 kDa), to oligosaccharides, oligonucleotides and polypeptides, antibodies, up to small proteins (~300 kDa). It is highly sensitive, requiring only femtomoles of sample. Desorption/ionization on silicon (DIOS) is similar to MALDE, but without the matrix. The sample is deposited directly on a nanostructured (porous silicon) surface and the sample desorbed directly from the nanostructured surface through the adsorption of laser light energy. DIOS has been used to analyze organic molecules, metabolites, biomolecules and peptides, and, ultimately, to image tissues and cells.
For much of the early 12th century, the Wadi al-Taym and the southern Chouf were the territory of the Jandal, a Druze clan. The leader of the clan, Dahhak ibn Jandal allied with the Crusaders of the Kingdom of Jerusalem and engaged in a feud with the Assassins who ruled the Banias fortress in the western foothills of Mount Hermon just south of Wadi al-Taym. Today, the population in the area being predominantly Druze and Sunni, with a high number of Christians, mostly Greek Orthodox.
Sources: en.wikipedia.org
==== Neutral loss scan ==== In the neutral loss scan method both Q1 and Q3 are scanned together, but with a constant mass offset. This allows the selective recognition of all ions which, by fragmentation in q2, lead to the loss of a given neutral fragment (e.g., H2O, NH3). Similar to the precursor ion scan, this method is useful in the selective identification of closely related compounds in a mixture.
== History == The company (the Ranpak name standing for Random Packaging) traces its origins to a machine patented by George R. Johnson in 1970 that converted kraft paper into shock absorbing crinkled paper for use in cushioning auto-parts to prevent such items being damaged in shipment. Johnson, working with entrepreneur and engineer, Raymond Q. Armington, an inventor with several packing- and storage related patents to his name, incorporated the company in 1972. Armington became its chairman, a position he held until his death in 1993. In early 2002, David M. Gabrielsen was appointed president and CEO of Ranpak replacing Steven E. Armington, son of the co-founder. In December 1991 Ranpak opened its first foreign manufacturing center in Heerlen, Holland. The plant produced packing material and packing machines for the European market. Ranpak's acquisitions include:
Barcodes – The barcode was invented in 1948. However, NASA developed a type of barcode label that could endure in space environments. Cordless power tools – The first cordless power tool was unveiled by Black & Decker in 1961. These were used by NASA and a number of spinoff products came out of those projects such as portable cordless vacuums. Magnetic resonance imaging (MRI), best known as a device for body scanning. NASA contractor JPL developed digital signal processing, which has applications in medical imaging used by MRIs. However, JPL works like a department of NASA. Microchip – The first hybrid integrated circuit was developed by Texas Instruments in 1958, and then the silicon integrated circuit microchip was invented by Robert Noyce at Fairchild Semiconductor in 1959. The impact of NASA was in creating a massive impetus for development in this area. Quartz clocks – The first quartz clock was invented in 1927. However, in the late 1960s, NASA partnered with a company to make a highly accurate quartz clock. Smoke detectors – NASA's connection to the modern smoke detector is that it developed one with adjustable sensitivity as part of the Skylab project; this development helps with nuisance tripping. Space Pen – An urban legend states that NASA spent a large amount of money to develop a pen that would write in space (the result purportedly being the Fisher Space Pen), while the Soviets used pencils. While NASA did spend funds to create a pen to work in space, the project was cancelled due to public opposition, and U.S.
Ayahuma bark: Cannon Ball tree. Provides protection and is used in healing susto (soul loss from spiritual fright or trauma). Capirona bark: Provides cleansing, balance and protection. It is noted for its smooth bark, white flowers, and hard wood. Chullachaki caspi bark (Byrsonima christianeae): Provides cleansing to the physical body. Used to transcend physical body ailments. Lopuna blanca bark: Provides protection. Punga amarilla bark: Yellow Punga. Provides protection. Used to pull or draw out negative spirits or energies. Remo caspi bark: Oar Tree. Used to move dense or dark energies. Wyra (huaira) caspi bark (Cedrelinga catanaeformis): Air Tree. Used to create purging, transcend gastro/intestinal ailments, calm the mind, and bring tranquility. Shiwawaku bark: Brings purple medicine to the ceremony. Uchu sanango: Head of the sanango plants. Huacapurana: Giant tree of the Amazon with very hard bark. Bobinsana (Calliandra angustifolia): Mermaid Spirit. Provides major heart chakra opening, healing of emotions and relationships.
=== 2018–present: Cool Blue Jewels and Pink Python === On February 9, 2018, Riff Raff and DJ Afterthought released the album Cool Blue Jewels with features from Wiz Khalifa, Chevy Woods, Jimmy Wopo, Young Buck and Project Pat, among others. On November 9, 2018, Riff Raff released a mixtape titled Tangerine Tiger with guest appearances from Z-Ro, Lil Tracy, Ricki Rich among others. On April 12, 2019, Riff Raff released his third studio album titled Pink Python with guest appearances from Chief Keef, J-Dawg, and Killah Priest. Riff Raff premiered his single "Jazzmine" with the Houston Chronicle, a remake of "A Whole New World" from Aladdin featuring Iliana Eve, Jonathan Hay, Aneesa Badshaw, Ranna Royce and others. On October 25, 2019, Riff Raff released his fourth studio album titled Cranberry Vampire, with appearances from Simon Rex, Andy Milonakis, Chief Keef, and others.
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.